Squibb/Novo-Nordisk
Executive Summary
CNS drug development and co-marketing agreement, announced by Squibb May 2, expands relationship between the firms beyond insulin to central nervous system disease therapies for depression, anxiety and psychosis. The deal was signed in first quarter and announced by Squibb at its annual meeting. In depression area, Novo-Nordisk has been working on dopamine reuptake inhibitors. GBR-12909 is currently in Phase II clinicals in Europe. Other CNS compounds are: FD- 10571, a non-benzodiazapine anxiolytic; FG-8119, a partial benzodiazapine receptor agonist; and fexometine,a 5-HT reuptake inhibitor with antidepressant properties.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.